— AstraZeneca Plc (NYSE: AZN) reported its third-quarter 2019 earnings of $0.23 per share and core earnings of $0.99 per share. This is compared to $0.45 per share expected.
— Total revenue increased by 20% to $6.41 billion versus $6.18 billion expected. This is driven by a 16% jump in product sales.
— Oncology sales jumped by 46% and respiratory sales grew by 15%. Biopharmaceuticals sales increased by 12% and new CVRM sales rose by 8% while sales in other medicines fell by 9%.
— Looking ahead into the full year 2019, the company reiterates its core earnings guidance in the range of $3.50 to $3.70 per share.
— The core operating profit for fiscal 2019 is predicted to increase ahead of product sales.
— For the full year, capital expenditure is anticipated to be broadly stable and restructuring expenses are targeted to reduce versus the prior-year.
Most Popular
Earnings calendar for the week of May 17
Benchmark stock indexes pared their recent gains early this week amid elevated inflation concerns, but regained a part of the momentum later aided by recovery in tech stocks. The Dow
Alibaba (BABA): The good and the bad from the Q4 earnings report
Shares of Alibaba Group (NYSE: BABA) have dropped 10% since the beginning of the year. The company reported mixed results for the fourth quarter of 2021 a day ago, with
Walt Disney (DIS) is focused on reopening, to put up a better show this year
With some of its parks and resorts either closed or operating at reduced capacity even more than a year after the virus outbreak, The Walt Disney Company (NYSE: DIS) is
